Get in Close Proximity with a Global Community of Experts
The TPD & Induced Proximity Summit Europe offers a unique opportunity to position your brand at the heart of proximity-based drug development. With the field rapidly expanding beyond oncology into neurodegeneration and immunology, drug developers are actively seeking external support to overcome key challenges in hit discovery, rational design, and translational validation.
By partnering with the summit, you will gain direct access to decision-makers from leading biopharma companies who are looking for discovery platforms, chemistry services, and preclinical CROs to accelerate their pipelines. With over 8 hours of built-in networking, a focused single-track format, and a curated audience of proximity innovators, your brand will be front and centre in conversations that shape the future of PROTACs, molecular glues, and emerging modalities.
Whether you're supporting early-stage discovery or enabling clinical readiness, this is your chance to connect with the team’s driving innovation within proximity therapeutics.
What to Expect?
Meet New Clients
Connect face-to-face with senior scientists, biotech founders, and pharma decision-makers actively seeking external support for PROTACs, molecular glues, and emerging proximity modalities.
Position Your Brand in Proximity Innovation
Gain visibility among Europe's most forward-thinking drug developers by featuring your logo across the summit website, brochure, and on-site signage.
Demonstrate Your Expertise
Showcase your capabilities in discovery, chemistry, or preclinical services through speaking opportunities, branded exhibition space, or poster presentations aligned with the summit’s focused single-track format.
Gain Strategic Market Insights
Hear directly from leading companies including GSK, Abbvie, Amphista, Autotac Bio & more to understand evolving outsourcing needs, modality trends, and translational challenges in the TPD space.
Key Services & Solutions
Our attendees from biopharma dedicated to induced proximity therapeutics are looking for service and solution providers with capabilities in the below areas but not limited to:
1. Hit Identification & Screening Platforms
Support early-stage discovery with DEL libraries, fragment-based approaches, and phenotypic screening tools tailored to proximity-based modalities.
2. Medicinal Chemistry & Compound Synthesis
Enable rational design and optimization of PROTACs, molecular glues, and stabilizers through synthesis services, purity analytics, and linker chemistry expertise.
3. Preclinical CRO Services
Provide tailored assays for degradation efficiency, target occupancy, PK/PD modelling, and toxicity profiling to validate proximity drug candidates.
4. Structural Biology & Proteomics
Offer deep mechanistic insights into ternary complex formation and protein-protein interactions to guide glue and degrader development.
5. Computational Modelling & AI Platforms
Accelerate rational design and screening with predictive tools for ligand binding, ternary complex modelling, and glue discovery.
6. Ligase Discovery & Validation Services
Help expand the E3 ligase toolbox with platforms for ligase mapping, degron identification, and tissue-specific targeting.
7. Biologic Engineering & Conjugation Technologies
Support development of antibody-based degraders and extracellular modalities through bispecific formats, nanobody scaffolds, and conjugation strategies.
8. Clinical Development & Translational Support
Assist with IND-enabling studies, formulation, and dose optimization to move proximity therapeutics from preclinical to clinical stages.
Audience Composition
Company Type
Attendee Seniority
Attending Companies Include
Get in Touch
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us if you would like to get involved and discuss a bespoke package suited to your needs.
Tom Walsh
Partnerships Director